Skip to main content

Table 1 Currently approved nanomedicines in the clinic

From: Cancer nanomedicine: a review of recent success in drug delivery

Year approved Name Type Active drug Diameter (references) Type of cancer
Japan (1994) Zinostatin stimalamer Polymer protein conjugate Styrene maleic anhydride neocarzinostatin (SMANCS) * Renal cancer
FDA (1995)
EMA (1996)
Doxil/caelyx Liposome (PEGylated) Doxorubicin 80–90 nm [82] HIV-associated Kaposi’s sarcoma, ovarian cancer, metastatic breast cancer, multiple myeloma
FDA (1996) DaunoXome Liposome (non-PEGylated) Daunorubicin 45 nm [83] HIV-associated Kaposi’s sarcoma
Taiwan (1998) Lipo-Dox Liposome Doxorubicin 180 nm [84] Kaposi’s sarcoma, breast and ovarian cancer
FDA (1999) DepoCyt Liposome Cytosine arabinoside (cytarabine) 10–20 µm [84] Neoplastic meningitis
EMA (2000) Myocet Liposome Doxorubicin 190 nm [84] Breast cancer
FDA (2005)
EMA (2008)
Abraxane Nanoparticle albumin bound Paclitaxel 130 nm [27] Advanced non-small-cell lung cancer, metastatic pancreatic cancer, metastatic breast cancer
FDA (2006) Oncaspar PEG protein conjugate l-Asparaginase 50–200 nm [84] Leukemia
South Korea (2007) Genexol-PM PEG-PLA polymeric micelle Paclitaxel 20–50 nm [85] Breast cancer, Lung cancer, Ovarian cancer [126]
EMA (2009) MEPACT Liposome (non-PEGylated) Mifamurtide * Osteosarcoma
EMA (2010) NanoTherm Iron oxide nanoparticle 20 nm [86] Thermal ablation glioblastoma
FDA (2012) Marqibo Liposome (non-PEGylated) Vincristine 100 nm [87] Philadelphia chromosome negative acute lymphoblastic leukemia
FDA (2015) MM-398 (Onivyde) Liposome (PEGylated) Irinotecan 80–140 nm [88] Metastatic pancreatic cancer (2nd line)
  1. * Data could not be found